<div id="readability-page-1"><p>Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 795,862 shares,  a growth of 55.5% from the December 31st total of 511,832 shares. Based on an average trading volume of 201,898 shares, the short-interest ratio is currently 3.9 days. Currently, 6.8% of the company's shares are sold short. Currently, 6.8% of the company's shares are sold short. Based on an average trading volume of 201,898 shares, the short-interest ratio is currently 3.9 days.</p><div><p><span></span><span>Get <strong>Forte Biosciences</strong> alerts:</span></p></div><h2>Forte Biosciences Trading Up 0.2%</h2><p>FBRX traded up $0.05 during midday trading on Friday, hitting $29.27. 215,740 shares of the company traded hands, compared to its average volume of 215,521. Forte Biosciences has a 52-week low of $4.90 and a 52-week high of $35.62. The company has a market capitalization of $366.67 million, a price-to-earnings ratio of -8.82 and a beta of 3.22. The business has a 50 day simple moving average of $25.79 and a two-hundred day simple moving average of $17.04. </p><p>Forte Biosciences (NASDAQ:FBRX - Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.99) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05.  Equities research analysts anticipate that  Forte Biosciences will post -12.12 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><p>Several brokerages have issued reports on FBRX. Chardan Capital  reiterated a &#34;buy&#34; rating and set a $61.00 target price on shares of Forte Biosciences in a report on Monday, November 17th. Wall Street Zen downgraded Forte Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 15th. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Forte Biosciences in a research note on Monday, December 29th. Finally, Evercore ISI initiated coverage on Forte Biosciences in a research note on Tuesday, November 25th. They issued an &#34;outperform&#34; rating and a $65.00 price objective for the company. Three analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $67.00.</p><p><b>Check Out Our Latest Research Report on Forte Biosciences</b></p><h2>Institutional Investors Weigh In On Forte Biosciences</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of FBRX. Bank of America Corp DE raised its position in shares of  Forte Biosciences by 5,641.8% during the 3rd quarter. Bank of America Corp DE now owns 3,158 shares of the company's stock valued at $47,000 after buying an additional 3,103 shares during the period.  Dimensional Fund Advisors LP acquired a new stake in shares of  Forte Biosciences during the third quarter worth about $161,000.  AlphaQuest LLC boosted its position in  Forte Biosciences by 300.7% in the 2nd quarter. AlphaQuest LLC now owns 16,897 shares of the company's stock valued at $218,000 after buying an additional 12,680 shares during the period.  Citadel Advisors LLC acquired a new position in  Forte Biosciences during the 3rd quarter worth $234,000.  Finally, Envestnet Asset Management Inc. acquired a new position in shares of  Forte Biosciences during the second quarter worth about $244,000. 77.63% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Forte Biosciences</h2> (Get Free Report)<p>Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.  </p><p>The company's lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.</p><h2>See Also</h2><ul><li>Five stocks we like better than Forte Biosciences</li><li>Do not delete, read immediately</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Forte Biosciences Right Now?</h2><p>Before you consider Forte Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forte Biosciences wasn't on the list.</p><p>While Forte Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Forte Biosciences, Inc. (NASDAQ:FBRX) experienced a significant increase in short interest, rising 55.5% to 795,862 shares as of January 15th. This increase is from 511,832 shares on December 31st, resulting in a short-interest ratio of 3.9 days based on an average daily volume of 201,898 shares. Currently, 6.8% of the company's stock is sold short. The stock traded up 0.2% to $29.27, with a market cap of $366.67 million. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and an average price target of $67.00.</p>

Market Beat

iShares Global Healthcare

iShares Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Forte Biosciences

iShares US Pharma

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Expands By 55.5%